A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.
- Autoimmune Hemolytic Anemia
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Diagnosis of AIHA based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test.
- Participants who have disease progression after treatment with standard therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
- Hemoglobin 7 to 10 g/dL.
- No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying conditions.
- Eastern Cooperative Oncology Group performance status of 0 to 2.
- Willingness to avoid pregnancy or fathering children.
- Pregnant or breastfeeding women.
- Concurrent conditions and history of other protocol-specified diseases.
- ANC < 1.5 × 10^9/L.
- Platelet count < 100 × 10^9/L.
- Severely impaired liver function.
- Impaired renal function with estimated creatinine clearance less than 45 mL/min.
- Anti-phospholipid antibodies positive or elevated anti-streptolysin antibodies.
- Positive serology test results for hepatitis B surface antigen or core antibody, or hepatitis C virus antibody with detectable RNA at screening, consistent with active or chronic infection.
- Known HIV infection or positivity on immunoassay.
- History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful.
- Known hypersensitivity or severe reaction to parsaclisib or its excipients.
- Phase 2
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- None (Open Label)
|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.||
|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period.||
- Incyte Corporation
Study ContactIncyte Corporation Call Center (US)